Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

206.36B

Market cap206.36B

Price-Earnings ratio

11.32

Price-Earnings ratio11.32

Dividend yield

2.65%

Dividend yield2.65%

Average volume

17.18M

Average volume17.18M

High today

$46.11

High today$46.11

Low today

$45.50

Low today$45.50

Open price

$45.98

Open price$45.98

Volume

5.80M

Volume5.80M

52 Week high

$64.16

52 Week high$64.16

52 Week low

$35.12

52 Week low$35.12

NVO News

The Motley Fool 1h

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NVO -0.91%) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the compan...

TipRanks 2h

Novo Nordisk Completes Key Oral Semaglutide Study in Japan: What Investors Should Watch

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

TipRanks 2h

Novo Nordisk’s SEMA-CardioDiab Hungary Study: What Real-World Oral Semaglutide Data Could Mean for NVO Investors

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

Analyst ratings

57%

of 37 ratings

Buy

35.1%

Hold

56.8%

Sell

8.1%

More NVO News

The Motley Fool 2h

Lexicon Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and Director - Mike Exton Senior Vice President...

Seeking Alpha 3h

Novo Nordisk CEO Doustdar says obesity drugs market won't be dominated by one player

Novo Nordisk (NVO) CEO Mike Doustdar believes that the market for obesity drugs won't end up in a winner-takes-all battle as consumers are searching for options...

TipRanks 3h

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly

Novo Nordisk (NVO) CEO Mike Doustdar is defending the European drug maker’s lawsuit against U.S. rival Eli Lilly (LLY) over what it alleges is false advertising...

24/7 Wall St. 5h

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover By Trey Thoelcke Published Aug 13, 9:05AM EDT Quick Read WVE sits 69% below its...

TipRanks 5h

Novo Nordisk Stock Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly

Shares in Danish drugmaker Novo Nordisk (NVO) fell about 2% to roughly $46 per share early Thursday. The decline came even though CEO Mike Doustar told Reuters...

CNBC 18h

Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer - CNBC

...

Simply Wall St 22h

Novo Nordisk Stock Still Looks Cheap On Earnings But Faces Growth Doubts

Novo Nordisk stock has pulled back sharply over the last three years, yet the company still screens as attractively valued on several checks. Recent news on obe...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.